The size of the global BCG vaccine market is predicted to grow at a CAGR of 5.1% from 2019 to 2024.
BCG vaccine stands for Bacillus Calmette-Gurin (BCG) vaccine. It prevents TB and is the only vaccine in the market, which could do that. A single dose is given to an infant soon after birth in countries with a high occurrence of TB. In countries in which TB is not a common occurrence, only high-risk infants are treated with it. Adults are only treated with this vaccine if their exposure to drug-resistant TB is a regular occurrence.
Albert Calmette and Camille Guérin produced the original strain of BCG in 1924 at the Pasteur Institute. BCG vaccine is used against Tuberculosis. Tuberculosis is a severe infection, which causes in the lungs, sometimes in other parts of the body. Vaccine Dose is given to healthy babies after birth because, at that age, they are at high risk to get immunized. The Bacille Calmette-Guerin vaccine is one of the most widely used as per the current vaccines. It is a part of the national childhood immunization program. The BCG vaccine included types that are Immune BCG and Therapy BCG. BCG vaccine is also used to treat against other mycobacterial infections, such as Buruli ulcer diseases. The World Health Organization (WHO) gives the estimate that TB caused to 10million people and claimed 1.6 million lives in 2017.
The increasing number of cases of TB all over the world particularly in the developing countries of APAC, rapid advancements in technology in the field of medical research on vaccines, and favourable government policies and initiatives with improved funding are driving the growth of this market.
The demand for BCG vaccine is increasing day by day, as the rising birth rate population. Also, the spread rate of the Tuberculosis in the adult stage of the community will boost the demand in the forecast period. The stage-wise vaccines for Tuberculosis have a higher need in the future. The increasing epidemic diseases in the future can decide the rising demand for the BCG Vaccine as well as BCG vaccine pipeline evolution will influence supply and demand dynamics.
Recently, WHO Preferred product characteristics, document for new develop an upcoming vaccine for Tuberculosis the primary concern to create this vaccine was to protect pulmonary TB in adults, and the production of new TB vaccine with better efficacy and safety than BCG to control neonates and infants. Currently in an investigation was found that the TB vaccine participant (M72/AS01E) was found protected against TB in clinical trial Phase II was conducted in Kenya, Zambia and South Africa with the evidence of latent tuberculosis infection the trial was conducted by the Glaxo Smith Klein (GSK). By focusing on the regional expansion, leading segments, key opportunities and rising trends and vendor landscape, Freeze-Dried BCG vaccine market have incredible possibilities to grow. Continuous inspection of those studies is reasonable to ensure that the procurement practices allow sufficient time for supply adjustments.
The key challenge for the BCG vaccine market is continuous supply availability. UNICEF reported the shortfall of 16.7 million vaccines due to the less supply capacity. As well as the inflexibility in demand gives the challenge to the industry. Middle-income countries are also facing the issue of the supply, and in high-income countries, there is no further is happened after the first strain. The limited investments in the production of vaccine by Government also effect on the supply and production.
There are three risks mitigating interventions in three areas which are sharing, enhancing information between major health sectors, to work with other countries in tighter vaccine management and Expand investments in the BCG manufacturing process.
Furthermore, adverse side-effects of this vaccine and supply bottlenecks all around the world are expected to hinder market growth in the forecast period.
Market Size Available
2018 – 2024
2019 – 2024
By Demography, Product Type, Application, End-User and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, Asia Pacific, Latin America, Middle East, and Africa
Merck & Co., Inc., Sanofi Pasteur, Japan BCG Laboratory, China National Biotec Group, Serum Institute of India Pvt. Ltd., InterVax Ltd., GreenSignal Bio Pharma Limited (GSBPL), and Statens Serum Institute.
This research report on the Global BCG Vaccine Market has been segmented and sub-segmented into the following categories and calculated market size and forecast for each segment until 2024.
BCG Vaccine Market - By Demographics
Based on demography, Paediatrics is a clear market leader accounting for more than three-quarters of market share and is likely to gain even more in the forecast period.
BCG Vaccine Market - By Product Type
Based on product type, the immune BCG segment is expected to lead the market during the forecast period. It is because BCG vaccination has become mandatory in most of the countries as part of the national immunization program. Moreover, the efficacy of the vaccine is reduced if it is not administered in infancy. The usage of this vaccine is highest in Kenya. Polio and hepatitis B vaccines are usually administered alongside it.
BCG Vaccine Market - By End User
BCG Vaccine Market - By Application
North America accounted for the largest market share while Asia Pacific is expected to grow with the highest CAGR due to TB eradication campaigns going on in the developing countries.
Key participants in the global BCG vaccine market profiled in the report are:
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.2 Pediatrics (0-18 years)
5.1.3 Adults (19-35 years)
5.1.4 Y-o-Y Growth Analysis, By Demographics
5.1.5 Market Attractiveness Analysis, By Demographics
5.1.6 Market Share Analysis, By Demographics
5.2 Product Type
5.2.1 BCG Vaccine Market
5.2.2 Immune BCG
5.2.3 Therapy BCG
5.2.4 Y-o-Y Growth Analysis, By Product Type
5.2.5 Market Attractiveness Analysis, By Product Type
5.2.6 Market Share Analysis, By Product Type
5.3 End User
5.3.4 Y-o-Y Growth Analysis, By End User
5.3.5 Market Attractiveness Analysis, By End User
5.3.6 Market Share Analysis, By End User
5.4.4 Y-o-Y Growth Analysis, By Applications
5.4.5 Market Attractiveness Analysis, By Applications
5.4.6 Market Share Analysis, By Applications
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By Demographics
188.8.131.52 By Product Type
184.108.40.206 By End User
220.127.116.11 By Applications
6.1.4 Market Attractiveness Analysis
18.104.22.168 By Geographical Area
22.214.171.124 By Demographics
126.96.36.199 By Product Type
188.8.131.52 By End User
184.108.40.206 By Applications
6.1.5 Market Share Analysis
220.127.116.11 By Geographical Area
18.104.22.168 By Demographics
22.214.171.124 By Product Type
126.96.36.199 By End User
188.8.131.52 By Applications
6.2 North America
6.2.2 United States
6.4.6 South Korea
6.5 Latin America
6.5.5 Rest of Latin America
6.6 Middle East & Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Merck & Co., Inc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Sanofi Pasteur
8.3 Japan BCG Laboratory
8.4 China National Biotec Group (a subsidiary of China National Pharmaceutical Group Corporation)
8.5 Serum Institute of India Pvt. Ltd.
8.6 InterVax Ltd.
8.7 GreenSignal Bio Pharma Limited (GSBPL)
8.8 Statens Serum Institute
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures